<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">OJST</journal-id><journal-title-group><journal-title>Open Journal of Stomatology</journal-title></journal-title-group><issn pub-type="epub">2160-8709</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ojst.2017.710037</article-id><article-id pub-id-type="publisher-id">OJST-79499</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Increased Expression of 11&lt;i&gt;β&lt;/i&gt;-Hydroxysteroid Dehydrogenase Type 1 in Experimental Periodontitis Induced by Lipopolysaccharide from &lt;i&gt;Porphyromonas gingivalis&lt;/i&gt;
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Atsuko</surname><given-names>Fujita</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Takaya</surname><given-names>Nakata</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Makoto</surname><given-names>Umeda</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Hiroaki</surname><given-names>Masuzaki</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Hirofumi</surname><given-names>Sawai</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>Division of Endocrinology, Diabetes and Metabolism, Hematology, Rheumatology, Graduate School of Internal Medicine, University of the Ryukyus, Okinawa, Japan</addr-line></aff><aff id="aff2"><addr-line>Department of Periodontology, Osaka Dental University, Osaka, Japan</addr-line></aff><aff id="aff4"><addr-line>Department of Internal Medicine, Osaka Dental University, Osaka, Japan</addr-line></aff><aff id="aff1"><addr-line>Department of Periodontology, Graduate School of Dentistry, Osaka Dental University, Osaka, Japan</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>sawai@cc.osaka-dent.ac.jp(HS)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>29</day><month>09</month><year>2017</year></pub-date><volume>07</volume><issue>10</issue><fpage>429</fpage><lpage>438</lpage><history><date date-type="received"><day>25,</day>	<month>August</month>	<year>2017</year></date><date date-type="rev-recd"><day>27,</day>	<month>September</month>	<year>2017</year>	</date><date date-type="accepted"><day>30,</day>	<month>September</month>	<year>2017</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  It has been proposed that 11
  β-hydroxysteroid dehydrogenase type 1 (11
  β-HSD1), which activates glucocorticoids, plays a role in chronic inflammatory diseases including metabolic diseases, rheumatoid arthritis, and ulcerative colitis. We have recently reported that the expression of 11
  β-HSD1 is increased in the gingiva of patients with chronic periodontitis and in that of rats with ligature-induced periodontitis. In this study, to further demonstrate the involvement of 11
  β-HSD1 in chronic periodontitis, the expression of 11
  β-HSD1 was investigated in another rat model of experimental periodontitis induced by intragingival injection of lipopolysaccharide from 
  Porphyromonas gingivalis (LPS-PG). Alveolar bone loss was observed two weeks after intragingival injection of LPS-PG. The level of 11
  β-HSD1 mRNA assessed by real-time re
  verse transcriptase-polymerase chain reaction was significantly elevated in LPS-PG-induced periodontitis compared with controls. The expression of 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2), which inactivates glucocorticoids, was not significantly different between control and LPS-PG-induced periodontitis. The expression of 11β-HSD1 was significantly correlated with that of TNF in LPS-PG-induced periodontitis. The increased expression of 11β-HSD1 protein in LPS-PG-induced periodontitis was confirmed by immunohistochemistry using anti-11β-HSD1 antibody. These results further suggest a role for 11β-HSD1 in the pathogenesis of chronic periodontitis.
 
</p></abstract><kwd-group><kwd>Chronic Periodontitis</kwd><kwd> 11&lt;i&gt;β&lt;/i&gt;-Hydroxysteroid Dehydrogenase Type 1</kwd><kwd> Lipopolysaccharide</kwd><kwd> &lt;i&gt;Porphyromonas gingivalis&lt;/i&gt;</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>It is well known that glucocorticoids play various roles in the metabolism of nutrients and immune responses [<xref ref-type="bibr" rid="scirp.79499-ref1">1</xref>] . Among many enzymes involved in the biosynthesis and catabolism of glucocorticoids, 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) mainly catalyzes the conversion of inactive glucocorticoids (cortisone in humans and 11-dehydrocorticosterone in rodents) into active glucocorticoids (cortisol in humans and corticosterone in rodents), whereas 11β- hydroxysteroid dehydrogenase type 2 (11β-HSD2) mainly catalyzes the conversion of active glucocorticoids into inactive glucocorticoids [<xref ref-type="bibr" rid="scirp.79499-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.79499-ref3">3</xref>] . It has been proposed that 11β-HSDs play a pivotal role in the intracellular regulation of glucocorticoids.</p><p>The involvement of 11β-HSD1 in metabolic diseases including obesity and diabetes mellitus has been reported [<xref ref-type="bibr" rid="scirp.79499-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.79499-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.79499-ref6">6</xref>] . The expression of 11β-HSD1 was elevated in adipocytes in the visceral fat of patients with obesity. Animal studies revealed that 11β-HSD1-deficient mice were protected against overnutrition [<xref ref-type="bibr" rid="scirp.79499-ref7">7</xref>] . Furthermore, transgenic mice overexpressing 11β-HSD1 selectively in adipose tissue developed metabolic phenotypes including visceral fat obesity, dyslipidemia, insulin resistance, and hypertension [<xref ref-type="bibr" rid="scirp.79499-ref8">8</xref>] [<xref ref-type="bibr" rid="scirp.79499-ref9">9</xref>] . Since several inhibitors of 11β-HSD1 ameliorate metabolic diseases in animal models [<xref ref-type="bibr" rid="scirp.79499-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.79499-ref11">11</xref>] , selective and potent 11β-HSD1 inhibitors have been developed for the treatment of metabolic diseases [<xref ref-type="bibr" rid="scirp.79499-ref12">12</xref>] [<xref ref-type="bibr" rid="scirp.79499-ref13">13</xref>] .</p><p>Since obesity is regarded as a chronic inflammatory disease of adipose tissue [<xref ref-type="bibr" rid="scirp.79499-ref14">14</xref>] [<xref ref-type="bibr" rid="scirp.79499-ref15">15</xref>] , the involvement of 11β-HSD1 in other chronic inflammatory diseases was examined. As expected, the expression of 11β-HSD1 was increased in chronic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel diseases [<xref ref-type="bibr" rid="scirp.79499-ref16">16</xref>] [<xref ref-type="bibr" rid="scirp.79499-ref17">17</xref>] [<xref ref-type="bibr" rid="scirp.79499-ref18">18</xref>] [<xref ref-type="bibr" rid="scirp.79499-ref19">19</xref>] . We recently reported that the expression of 11β-HSD1 was increased in gingival tissues of patients with another chronic inflammatory disease, chronic periodontitis [<xref ref-type="bibr" rid="scirp.79499-ref20">20</xref>] . Moreover, we reported that the expression of 11β-HSD1 was also increased in ligature-induced experimental periodontitis in rats [<xref ref-type="bibr" rid="scirp.79499-ref21">21</xref>] . To further demonstrate the involvement of 11β-HSD1 in chronic periodontitis, another rat model of experimental periodontitis induced by intragingival injection of lipopolysaccharide (LPS) from Porphyromonas gingivalis was used in this study.</p></sec><sec id="s2"><title>2. Materials and Methods</title><sec id="s2_1"><title>2.1. Experimental Animals</title><p>Fifty-two six-week-old male Wistar rats were purchased from Shimizu Laboratory Supplies (Kyoto, Japan). Rats were maintained under specific pathogen-free conditions in the Osaka Dental University Animal Care facility. The use of animals and experimental protocol were approved by the Committee for Animal Experiments of Osaka Dental University (#17-02018). The experimental procedures were executed in accordance with the Guidelines for Animal Experiments of Osaka Dental University.</p></sec><sec id="s2_2"><title>2.2. Induction of Periodontitis by Intragingival Injection of LPS from Porphyromonas gingivalis</title><p>Forty-six rats at seven weeks of age were anesthetized by inhalation of isoflurane (Wako Pure Chemical industries, Osaka, Japan) and intraperitoneal injection of pentobarbital (0.3 mg/kg) (Kyoritsu Seiyaku Corporation, Tokyo, Japan). Periodontitis was induced by intragingival injection of LPS from Porphyromonas gingivalis (LPS-PG) (InvivoGen, San Diego, CA, USA). LPS-PG was dissolved in endotoxin-free water at concentrations of 0.01, 0.1, and 1 mg/ml, and 5 μl of LPS-PG (for controls 5 μl of endotoxin-free water) was injected into the palatal gingiva around the second maxillary molars using a 31-gauge needle equipped with a gastight syringe (Hamilton Company, Reno, NV, USA) on day 1, day 3, and day 5.</p></sec><sec id="s2_3"><title>2.3. Micro-CT Analysis</title><p>For micro-CT analysis, 5 μl of 1 mg/ml LPS-PG was injected into the palatal gingiva around the second maxillary molars in three rats on day 1, day 3, and day 5, and rats were euthanized with an overdose of isoflurane and pentobarbital on day 14. Maxillary bones were excised and analyzed using a micro-CT scanner, SMX-130CT (Shimadzu Corporation, Kyoto, Japan) as described previously [<xref ref-type="bibr" rid="scirp.79499-ref21">21</xref>] . Three dimensional images were created using VGStudio MAX 1.2.1 software (Volume Graphics, GmbH, Germany).</p></sec><sec id="s2_4"><title>2.4. RNA Extraction</title><p>For RNA extraction, rats were euthanized with an overdose of isoflurane and pentobarbital on day 9. Palatal gingiva around the second maxillary molars were excised, and were homogenized in 1 ml Trizol Reagent (Thermo Fisher Scientific, Waltham, MA, USA). After incubation for 5 min, 0.2 ml chloroform was added and the mixture was incubated for 2 min. The mixture was centrifuged at 12,000 g for 15 min at 4˚C, and the upper phase was transferred to another tube. After addition of 0.5 ml isopropyl alcohol, the mixture was incubated for 10 min. Then the mixture was centrifuged at 12,000 g for 10 min at 4˚C. The supernatant was removed, and 1 ml of 75% ethanol was added to the RNA pellet. After centrifugation at 7500 g for 5 min at 4˚C, the supernatant was removed and the RNA pellet was air-dried. Then the RNA pellet was dissolved in nuclease-free water (Thermo Fisher Scientific, Waltham, MA, USA). The RNA concentration was determined by measuring the absorbance at 260 nm using a spectrophotometer, Smart Spec 3000 (Bio-Rad, Hercules, CA, USA).</p></sec><sec id="s2_5"><title>2.5. Real-Time Reverse Transcription-Polymerase Chain Reaction (RT-PCR)</title><p>TaqMan Gene Expression Assays for rat 11β-HSD1 (#Rn00567167_m1), rat 11β-HSD2 (#Rn00492539_m1), rat tumor necrosis factor (TNF) (#Rn999990- 17_m1), and rat glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (#Rn01- 7757-63_g1) were purchased from Applied Biosystems (Foster City, CA, USA). RT-PCR was performed using the Taq Man RNA-to-CT 1-Step Kit and Step One Plus Real Time PCR System (Applied Biosystems, Foster City, CA, USA). As a template, 20 ng RNA was used for each sample. RNA was mixed with 0.5 μl RT Enzyme Mix, 10 μl RT-PCR Mix, 1 μl Gene Expression Assay, and nuclease-free water (total volume 20 μl). The mixture was incubated for 15 min at 48˚C for reverse transcription, and for 10 min at 95˚C for activation of DNA polymerase. Then the mixture was incubated for 15 sec at 95˚C for denaturing and for 1 min at 60˚C for annealing/extension for 49 cycles. All reactions were carried out in triplicate. For normalization, the ratios of 11β-HSD1, 11β-HSD2, and TNF mRNA versus GAPDH mRNA were calculated in each sample.</p></sec><sec id="s2_6"><title>2.6. Immunohistochemistry</title><p>For immunohistochemistry, 5 μl of 1 mg/ml LPS-PG was injected into the palatal gingiva around the second maxillary molars in three rats on day 1, day 3, and day 5, and rats were euthanized with an overdose of isoflurane and pentobarbital on day 9. After euthanasia, the rats were perfused with 10% formaldehyde neutral buffer solution (Sigma-Aldrich, St. Louis, MO, USA). The maxillary bones were excised and fixed in 10% formaldehyde neutral buffer solution at 4˚C for 7 days. Then the bones were decalcified in a rapid decalcification solution, K-CX (Falma, Tokyo, Japan) at 4˚C for 24 h, followed by conventional dehydration and paraffin embedding. After cutting into 5 μm-thick sections, the specimens were deparaffinized and stained with hematoxylin-eosin (HE) or immunostained with rabbit anti-11β-HSD1 monoclonal antibody (abcam, Cambridge, UK) and Envision + kit/HRP (DAB) (Dako, Glostrup, Denmark). Images were captured using an all-in one microscope, BZ-9000 (Keyence, Osaka, Japan).</p></sec><sec id="s2_7"><title>2.7. Statistical Analysis</title><p>One-way analysis of variance followed by a post-hoc test (Tukey) and significance testing of Pearson’s correlation coefficient were performed using SPSS software version 21.0 (IBM, Armonk, NY, USA).</p></sec></sec><sec id="s3"><title>3. Results</title><sec id="s3_1"><title>3.1. Micro-CT Analysis</title><p>In this study, experimental periodontitis was induced by intragingival injection of LPS from Porphyromonas gingivalis (LPS-PG) in rats. LPS-PG was injected into the palatal gingiva around the second maxillary molars on day 1, day 3, and day 5. Micro-CT analysis revealed alveolar bone loss around the second maxillary molar on day 14 (<xref ref-type="fig" rid="fig1">Figure 1</xref>(b)), demonstrating that experimental periodontitis was induced by LPS-PG injection.</p></sec><sec id="s3_2"><title>3.2. RT-PCR Analysis of 11β-HSD1, 11β-HSD2, and TNF mRNA</title><p>The expression levels of 11β-HSD1, 11β-HSD2, and TNF mRNA in rat gingiva were analyzed using real-time RT-PCR methods as described above. As shown in <xref ref-type="fig" rid="fig2">Figure 2</xref>(a), the ratio of 11β-HSD1 mRNA versus GAPDH mRNA was significantly higher in gingiva injected with 1 mg/ml LPS-PG than in controls injected with endotoxin-free water. The ratio of 11β-HSD2 mRNA versus GAPDH mRNA was not significantly increased in LPS-PG-injected gingiva compared with controls (<xref ref-type="fig" rid="fig2">Figure 2</xref>(b)). The expression of TNF, a common inflammatory cytokine, was significantly higher in 1 mg/ml LPS-PG-injected gingiva than in controls (<xref ref-type="fig" rid="fig2">Figure 2</xref>(c)). As shown in <xref ref-type="fig" rid="fig3">Figure 3</xref>, the expression of 11β-HSD1 was positively and significantly correlated with that of TNF, in accordance with our previous report [<xref ref-type="bibr" rid="scirp.79499-ref21">21</xref>] .</p></sec><sec id="s3_3"><title>3.3. Immunohistochemistry for 11β-HSD1 Protein</title><p>The expression of 11β-HSD1 at the protein level was examined by immunostaining using anti-11β-HSD1 antibody. HE-staining showed that inflammatory cells such as neutrophils were infiltrated in LPS-PG-injected gingiva (<xref ref-type="fig" rid="fig4">Figure 4</xref>(b)). Immunostaining demonstrated that many round cells (presumably inflammatory cells such as neutrophils and monocytes) were positively stained with anti-11β-HSD1 antibody in LPS-PG-injected gingiva (<xref ref-type="fig" rid="fig4">Figure 4</xref>(d)).</p></sec></sec><sec id="s4"><title>4. Discussion</title><p>We recently reported that the expression of 11β-HSD1 as well as the ratio of 11β-HSD1 versus 11β-HSD2 is elevated in gingiva of patients with chronic periodontitis and in ligature-induced experimental periodontitis in rats [<xref ref-type="bibr" rid="scirp.79499-ref20">20</xref>] [<xref ref-type="bibr" rid="scirp.79499-ref21">21</xref>] . In this paper, we have demonstrated that the expression of 11β-HSD1 is elevated in gingiva of rats with LPS-PG-induced experimental periodontitis. These results strongly suggest that 11β-HSD1 plays a role in the pathogenesis of chronic periodontitis.</p><p>The expression of 11β-HSD1 at the protein level was confirmed by immunostaining using anti-11β-HSD1 antibody. In our previous report, a polyclonal anti-11β-HSD1 antibody was used for immunostaining [<xref ref-type="bibr" rid="scirp.79499-ref21">21</xref>] . In contrast, a monoc-</p><p>lonal anti-11β-HSD1 antibody was used in this study, since the specificity of monoclonal antibodies is generally higher than that of polyclonal antibodies. Immunostaining revealed that round cells (presumably inflammatory cells) rather than spindle-shaped epithelial cells were stained with anti-11β-HSD1 antibody, suggesting that inflammatory cells express more 11β-HSD1 protein. In accordance with this result, it has been reported that monocytes/macrophages and neutrophils highly express 11β-HSD1 [<xref ref-type="bibr" rid="scirp.79499-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.79499-ref22">22</xref>] .</p><p>The involvement of 11β-HSD1 in chronic inflammatory diseases including metabolic diseases, rheumatic arthritis, and inflammatory bowel diseases has been proposed [<xref ref-type="bibr" rid="scirp.79499-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.79499-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.79499-ref6">6</xref>] [<xref ref-type="bibr" rid="scirp.79499-ref16">16</xref>] [<xref ref-type="bibr" rid="scirp.79499-ref17">17</xref>] [<xref ref-type="bibr" rid="scirp.79499-ref18">18</xref>] [<xref ref-type="bibr" rid="scirp.79499-ref19">19</xref>] . Since chronic periodontitis is thought to be a chronic inflammatory disease, we investigated the gingival expression of 11β-HSD1. As we expected, the gingival expression of 11β-HSD1 was increased in patients with chronic periodontitis and two rat models of experimental periodontitis. These results further suggest the involvement of 11β-HSD1 in chronic inflammation. However, the precise role of 11β-HSD1 in chronic inflammation remains to be determined. Since 11β-HSD1 mainly converts inactive glucocorticoids into active glucocorticoids, the increased expression of 11β-HSD1 would result in</p><p>increased levels of intracellular active glucocorticoids. Although glucocorticoids usually exert anti-inflammatory effects [<xref ref-type="bibr" rid="scirp.79499-ref1">1</xref>] , it has been reported that glucocorticoids may have pro-inflammatory effects under chronic inflammatory conditions [<xref ref-type="bibr" rid="scirp.79499-ref17">17</xref>] [<xref ref-type="bibr" rid="scirp.79499-ref23">23</xref>] . The pro-inflammatory effects of 11β-HSD1 have also been reported [<xref ref-type="bibr" rid="scirp.79499-ref24">24</xref>] [<xref ref-type="bibr" rid="scirp.79499-ref25">25</xref>] . Furthermore, the increased expression of 11β-HSD1 might play a role in alveolar bone loss resulting from chronic periodontitis, since glucocorticoids are known to stimulate bone resorption and suppress bone formation [<xref ref-type="bibr" rid="scirp.79499-ref26">26</xref>] . A recent report has suggested that glucocorticoids can potentiate alveolar bone loss in experimental periodontitis in rats [<xref ref-type="bibr" rid="scirp.79499-ref27">27</xref>] . Thus, further studies are required to elucidate the role of 11β-HSD1 in chronic periodontitis and alveolar bone loss.</p></sec><sec id="s5"><title>5. Conclusion</title><p>In conclusion, we demonstrated that the expression of 11β-HSD1 is increased in experimental periodontitis induced by intragingival injection of LPS-PG in rats. Since it was previously reported that the 11β-HSD1 expression was elevated in chronic periodontitis in humans and in ligature-induced experimental periodontitis in rats, these results further suggest a role for 11β-HSD1 in the pathogenesis of chronic periodontitis.</p></sec><sec id="s6"><title>Acknowledgements</title><p>This study was supported in part by a Grant-in-Aid for Scientific Research (C) from Japan Society for the Promotion of Science #25462941 (to H.S.).</p></sec><sec id="s7"><title>Conflicts of Interest</title><p>The authors declare that they have no conflicts of interest.</p></sec><sec id="s8"><title>Cite this paper</title><p>Fujita, A., Nakata, T., Umeda, M., Masuzaki, H. and Sawai, H. (2017) Increased Expression of 11β-Hydro- xysteroid Dehydrogenase Type 1 in Experimental Periodontitis Induced by Lipopolysaccharide from Porphyromonas gingivalis. Open Journal of Stomatology, 7, 429-438. https://doi.org/10.4236/ojst.2017.710037</p></sec></body><back><ref-list><title>References</title><ref id="scirp.79499-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Rhen, T. and Cidlowski, J.A. (2005) Antiinflammatory Action of Glucocorticoids—New Mechanisms for Old Drugs. The New England Journal of Medicine, 353, 1711-1723. https://doi.org/10.1056/NEJMra050541</mixed-citation></ref><ref id="scirp.79499-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Seckl, J.R. and Walker, B.R. (2001) Minireview: 11β-Hydroxysteroid Dehydrogenase Type 1—A Tissue-Specific Amplifier of Glucocorticoid Action. Endocrinology, 142, 1371-1376. https://doi.org/10.1210/endo.142.4.8114</mixed-citation></ref><ref id="scirp.79499-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Tomlinson, J.W., Walker, E.A., Bujalska, I.J., Draper, N., Lavery, G.G., Cooper, M.S., Hewison, M. and Stewart, P.M. (2004) 11β-Hydroxysteroid Dehydrogenase Type 1: A Tissue-Specific Regulator of Glucocorticoid Response. Endocrine Reviews, 25, 831-866. https://doi.org/10.1210/er.2003-0031</mixed-citation></ref><ref id="scirp.79499-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Bujalska, I.J., Kumar, S. and Stewart, P.M. (1997) Does Central Obesity Reflect ‘Cushing’s Disease of the Omentum’? Lancet, 349, 1210-1213. https://doi.org/10.1016/S0140-6736(96)11222-8</mixed-citation></ref><ref id="scirp.79499-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Rask, E., Olsson, T., Soderberg, S., Andrew, R., Livingstone, D.E., Johnson, O. and Walker, B.R. (2001) Tissue-Specific Dysregulation of Cortisol Metabolism in Human Obesity. The Journal of Clinical Endocrinology &amp; Metabolism, 86, 1418-1421. https://doi.org/10.1210/jcem.86.3.7453</mixed-citation></ref><ref id="scirp.79499-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Paulsen, S.K., Pedersen, S.B., Fisker, S. and Richelsen, B. (2007) 11β-HSD Type 1 Expression in Human Adipose Tissue: Impact of Gender, Obesity, and Fat Localization. Obesity, 15, 1954-1960. https://doi.org/10.1038/oby.2007.233</mixed-citation></ref><ref id="scirp.79499-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Kotelevtsev, Y., Holmes, M.C., Burchell, A., Houston, P.M., Schmoll, D., Jamieson, P., Best, R., Brown, R., Edwards, C.R., Seckl, J.R. and Mullins, J.J. (1997) 11β-Hydroxysteroid Dehydrogenase Type 1 Knockout Mice Show Attenuated Glucocorticoid-Inducible Responses and Resist Hyperglycemia on Obesity or Stress. Proceedings of the National Academy of Sciences of the United States of America, 94, 14924-14929. https://doi.org/10.1073/pnas.94.26.14924</mixed-citation></ref><ref id="scirp.79499-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Masuzaki, H., Paterson, J., Shinyama, H., Morton, N.M., Mullins, J.J., Seckl, J.R. and Flier, J.S. (2001) A transgenic Model of Visceral Obesity and the Metabolic Syndrome. Science, 294, 2166-2170. https://doi.org/10.1126/science.1066285</mixed-citation></ref><ref id="scirp.79499-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Masuzaki, H., Yamamoto, H., Kenyon, C.J., Elmquist, J.K., Morton, N.M., Paterson, J.M., Shinyama, H., Sharp, M.G., Fleming, S., Mullins, J.J., Seckl, J.R. and Flier, J.S. (2003) Transgenic Amplification of Glucocorticoid Action in Adipose Tissue Causes High Blood Pressure in Mice. The Journal of Clinical Investigation, 112, 83-90. https://doi.org/10.1172/JCI17845</mixed-citation></ref><ref id="scirp.79499-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Hermanowski-Vosatka, A., Balkovec, J.M., Cheng, K., Chen, H.Y., Hernandez, M., Koo, G.C., Le Grand, C.B., Li, Z., Metzger, J.M., Mundt, S.S., Noonan, H., Nunes, C.N., Olson, S.H., Pikounis, B., Ren, N., Robertson, N., Schaeffer, J.M., Shah, K., Springer, M.S., Strack, A.M., Strowski, M., Wu, K., Wu, T., Xiao, J., Zhang, B.B., Wright, S.D. and Thieringer, R. (2005) 11β-HSD1 Inhibition Ameliorates Metabolic Syndrome and Prevents Progression of Atherosclerosis in Mice. The Journal of Experimental Medicine, 202, 517-527. https://doi.org/10.1084/jem.20050119</mixed-citation></ref><ref id="scirp.79499-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Nuotio-Antar, A.M., Hachey, D.L. and Hasty, A.H. (2007) Carbenoxolone Treatment Attenuates Symptoms of Metabolic Syndrome and Atherogenesis in Obese, Hyperlipidemic Mice. American Journal of Physiology-Endocrinology and Metabolism, 293, E1517-E1528. https://doi.org/10.1152/ajpendo.00522.2007</mixed-citation></ref><ref id="scirp.79499-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Rosenstock, J., Banarer, S., Fonseca, V.A., Inzucchi, S.E., Sun, W., Yao, W., Hollis, G., Flores, R., Levy, R., Williams, W.V., Seckl, J.R., Huber, R. and INCB13739-202 Principal Investigators (2010) The 11-β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor INCB13739 Improves Hyperglycemia in Patients with Type 2 Diabetes Inadequately Controlled by Metformin Monotherapy. Diabetes Care, 33, 1516-1522. https://doi.org/10.2337/dc09-2315</mixed-citation></ref><ref id="scirp.79499-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Feig, P.U., Shah, S., Hermanowski-Vosatka, A., Plotkin, D., Springer, M.S., Donahue, S., Thach, C., Klein, E.J., Lai, E. and Kaufman, K.D. (2011) Effects of an 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor, MK-0916, in Patients with Type 2 Diabetes Mellitus and Metabolic Syndrome. Diabetes, Obesity and Metabolism, 13, 498-504. https://doi.org/10.1111/j.1463-1326.2011.01375.x</mixed-citation></ref><ref id="scirp.79499-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Hotamisligil, G.S. (2006) Inflammation and Metabolic Disorders. Nature, 444, 860-867. https://doi.org/10.1038/nature05485</mixed-citation></ref><ref id="scirp.79499-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Grant, R.W. and Dixit, V.D. (2015) Adipose Tissue as an Immunological Organ. Obesity, 23, 512-518. https://doi.org/10.1002/oby.21003</mixed-citation></ref><ref id="scirp.79499-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Hardy, R., Rabbitt, E.H., Filer, A., Emery, P., Hewison, M., Stewart, P.M., Gittoes, N.J., Buckley, C.D., Raza, K. and Cooper, M.S. (2008) Local and Systemic Glucocorticoid Metabolism in Inflammatory Arthritis. Annals of the Rheumatic Diseases, 67, 1204-1210. https://doi.org/10.1136/ard.2008.090662</mixed-citation></ref><ref id="scirp.79499-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Hardy, R.S., Raza, K. and Cooper, M.S. (2014) Glucocorticoid Metabolism in Rheumatoid Arthritis. Annals of the New York Academy of Sciences, 1318, 18-26. https://doi.org/10.1111/nyas.12389</mixed-citation></ref><ref id="scirp.79499-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Zbánková, S., Bryndová, J., Leden, P., Kment, M., Svec, A. and Pácha, J. (2007) 11β-Hydroxysteroid Dehydrogenase 1 and 2 Expression in Colon from Patients with Ulcerative Colitis. Journal of Gastroenterology and Hepatology, 22, 1019-1023. https://doi.org/10.1111/j.1440-1746.2006.04529.x</mixed-citation></ref><ref id="scirp.79499-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Stegk, J.P., Ebert, B., Martin, H.-J. and Maser, E. (2009) Expression Profiles of Human 11β-Hydroxysteroid Dehydrogenases Type 1 and Type 2 in Inflammatory Bowel Diseases. Molecular and Cellular Endocrinology, 301, 104-108.</mixed-citation></ref><ref id="scirp.79499-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Nakata, T., Fujita, A., Umeda, M., Yoshida, H., Inami, K., Masuzaki, H. and Sawai, H. (2016) The Increased Ratio of 11β-Hydroxysteroid Dehydrogenase Type 1 versus 11β-Hydroxysteroid Dehydrogenase Type 2 in Chronic Periodontitis Irrespective of Obesity. SpringerPlus, 5, 40. https://doi.org/10.1186/s40064-016-1679-6</mixed-citation></ref><ref id="scirp.79499-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Nakata, T., Umeda, M., Masuzaki, H. and Sawai, H. (2016) The Expression of 11β-Hydroxysteroid Dehydrogenase Type 1 Is Increased in Experimental Periodontitis in Rats. BMC Oral Health, 16, 108. https://doi.org/10.1186/s12903-016-0303-z</mixed-citation></ref><ref id="scirp.79499-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Coutinho, A.E., Kipari, T.M., Zhang, Z., Esteves, C.L., Lucas, C.D., Gilmour, J.S., Webster, S.P., Walker, B.R., Hughes, J., Savill, J.S., Seckl, J.R., Rossi, A.G. and Chapman, K.E. (2016) 11β-Hydroxysteroid Dehydrogenase Type 1 Is Expressed in Neutrophils and Restrains an Inflammatory Response in Male Mice. Endocrinology, 157, 2928-2936. https://doi.org/10.1210/en.2016-1118</mixed-citation></ref><ref id="scirp.79499-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Chapman, K.E., Coutinho, A.E., Zhang, Z., Kipari, T., Savill, J.S. and Seckl, J.R. (2013) Changing Glucocorticoid Action: 11β-Hydroxysteroid Dehydrogenase Type 1 in Acute and Chronic Inflammation. The Journal of Steroid Biochemistry and Molecular Biology, 137, 82-92.</mixed-citation></ref><ref id="scirp.79499-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Ishii, T., Masuzaki, H., Tanaka, T., Arai, N., Yasue, S., Kobayashi, N., Tomita, T., Noguchi, M., Fujikura, J., Ebihara, K., Hosoda, K. and Nakao, K. (2007) Augmentation of 11β-Hydroxysteroid Dehydrogenase Type 1 in LPS-Activated J774.1 Macrophages Role of 11β-HSD1 in Pro-Inflammatory Properties in Macrophages. FEBS Letters, 581, 349-354.</mixed-citation></ref><ref id="scirp.79499-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Ishii-Yonemoto, T., Masuzaki, H., Yasue, S., Okada, S., Kozuka, C., Tanaka, T., Noguchi, M., Tomita, T., Fujikura, J., Yamamoto, Y., Ebihara, K., Hosoda, K. and Nakao, K. (2010) Glucocorticoid Reamplification within Cells Intensifies NF-κB and MAPK Signaling and Reinforces Inflammation in Activated Preadipocytes. American Journal of Physiology-Endocrinology and Metabolism, 298, E930-E940. https://doi.org/10.1152/ajpendo.00320.2009</mixed-citation></ref><ref id="scirp.79499-ref26"><label>26</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Teitelbaum</surname><given-names> S.L. </given-names></name>,<etal>et al</etal>. (<year>2015</year>)<article-title>Glucocorticoids and the Osteoclast</article-title><source> Clinical and Experimental Rheumatology</source><volume> 33</volume>,<fpage> S37</fpage>-<lpage>S39</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.79499-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Sousa, L.H.T., Moura, E.V., Queiroz, A.L., Val, D., Chaves, H., Lisboa, M., Furlaneto, F., Brito, G.A. and Goes, P. (2017) Effects of Glucocorticoid-Induced Osteoporosis on Bone Tissue of Rats with Experimental Periodontitis. Archives of Oral Biology, 77, 55-61.</mixed-citation></ref></ref-list></back></article>